Jeffry Weinhuff

LPX50 constituent company, Apax Global Alpha Limited (AGA) has announced the sale of investment in Healthium Medtech Limited. According to the press release, this transaction values AGA's look-through investment in Healthium at approximately €22.7M. This represents an uplift of c.23% to the last Unaffected Valuation1 and an uplift of c.€4.3m (c.€0.01 per share / c.£0.01 per share) in the Adjusted Net Asset Value ("Adjusted NAV") of AGA at 31 March 2024. The transaction is expected to close in Q3 2024, subject to regulatory approvals. 🔷 Link to official press release 👉 https://lnkd.in/dTgqEV3w 🔷 Subscribe to Listed Private Equity Barometer published by LPX AG 👉 https://lnkd.in/ex-E8nej   Disclaimer: This content is provided for informational purposes and none of the content here should be construed as financial advice or an offer or solicitation for securities. The content is not intended to provide a sufficient basis on which to make an investment decision. The past performance is not indicative of future results.   #privateequity #alternativeinvestments #privatemarkets #investments #listedprivateequity #technology #business #investing #medical #health #healthcare

1

Diakonos Oncology CFO Anthony Baldor is at #BIO24 this week to make a company presentation and meet with potential partners and investors. For those interested in learning more about Diakonos’ unique dendritic cell vaccines for cancer, we can be reached through the BIO ONE Partnering System. Mr. Baldor’s company presentation takes place on Tuesday, June 4th at 3:00 pm PT in Company Presentation Theater 2 at the San Diego Convention Center. Mr. Baldor’s presentation will include a review of Diakonos’ highly differentiated double-loaded autologous dendritic cell vaccines for cancer, and an operational update on the company’s plans for growth, including clinical development outlook and expansion of its leadership team. Diakonos recently completed a Phase 1 trial of DOC1021, its lead vaccine for glioblastoma multiforme (GBM), and is planning a Phase 2 study. The US Food and Drug Administration has granted Fast Track and Orphan Drug status for DOC1021. Two other clinical trials are under way with dendritic cell vaccines targeting pancreatic cancer and angiosarcoma. “We are very excited about the results of our Phase 1 trial for GBM,” Mr. Baldor said. “Data observed to date give us great confidence in our dendritic cell vaccines and their potential to treat a broad range of solid tumor cancers, including the most deadly. Twelve month survival is currently at 90% for evaluable patients, and the therapy is well tolerated.” Diakonos’ dendritic cell vaccines activate robust cytotoxic TH1 cell signaling pathways that better harness a patient's immune system to target and eliminate cancer cells by initiating a natural immune response. This is achieved without any genetic modification of the patient’s immune cells, which greatly simplifies the manufacturing process and significantly reduces costs when compared to leading cell therapy approaches. Visit our we site: diakonosoncology.com to learn more. #cancerresearch #cancer #biopharma #clinicaltrials https://lnkd.in/dET5pqbD

25

5 Comments

Congrats to Brise Pharma for completing nearly USD 20 million in Pre-A and Pre-A+ rounds of financing! We at Qiming, a consistent supporter of the company's Seed and Angel rounds, have continued to participate in this round. The raised funds will be used for the development of Brise's pipeline in preclinical and clinical stages, particularly to accelerate the clinical trials of BR005, China's first independently developed CGRP class small molecule drug. Brise Pharma is committed to developing innovative, high specificity pain treatments, especially for severe chronic pain conditions – focusing largely on addressing unmet clinical needs for facial pain, musculoskeletal pain and neuropathic pain. Their vision is to provide safe, effective, and convenient pain management solutions to patients worldwide suffering from chronic pain, already having two drugs in clinical stages. Stay tuned for more updates on their incredible journey! https://lnkd.in/e3AAQe4T #QMportfolio #QMhealthcare #financing ##BrisePharma #QimingVenturePartners #InvestInInnovation #ChronicPainManagement #ClinicalTrials

10

Omnimed Equity Partners is a private equity firm that specializes in healthcare investments and includes both venture capital and private equity investments. With the rise of multi-drug-resistant bacteria, there is an urgent need for solutions that will allow hospitals to safely cure and prevent antibiotic-resistant infections. The firm is looking for founders developing groundbreaking technology that addresses this problem with next-generation clinical microbiology solutions that are based on phenotypic single-cell technology. Founders that can rapidly identify pathogens and determine their antibiotic response without the need for traditional time-consuming culture steps. The result is life-saving antibiotic treatment information up to four days faster compared to the standard of care. https://lnkd.in/gYr5riG5 #venturecapital #firm #healthcare #sector #founders

4

⏳ Last chance to register for the complimentary webinar "Capital Markets Preview: Patience, optimism, resilience, plus data" presented by BioCentury Inc. and Oppenheimer & Co. Inc. Investors and biopharma dealmakers are coming together for an in-depth discussion about where the biotech market is headed. Register to join us live on Thursday and ask questions, or watch the recorded version at your convenience: https://lnkd.in/gkZBPBaq Moderator: Stephen Hansen, BioCentury Inc. Panelists: Ario Arabi, Novartis Nina Kjellson, Canaan Partners Andrew W. Lam, PharmD, Ally Bridge Group Michael Margolis, Oppenheimer & Co. Inc. Nimish Shah, Venrock #biotech #biopharma #investors #dealmakers #capitalmarkets #VCs #capitalmarketspreview

2

May saw PE-VC investments dip to $3.2B, highlighting a yearly drop of $700M. Notable deals include @KKR_Co's notable Healthium Medtech buyout and @WarburgPincus investment in Shriram Housing Finance. #PrivateEquity #VentureCapital Trends

3

ARCH, founded in 1986, pioneers investments in groundbreaking science companies, committing $50K to hundreds of millions per venture. Specializing in early-stage biotech and healthcare, their global reach, with a U.S. focus, sets them apart. Notable investments include Editas Medicine and GRAIL. Renowned for contrarian, bold moves, ARCH navigates away from the crowd, relying on imaginative risk-taking. Investment Range: $50M - $500M Stage: Early Stage Sector: Biotechnology, Healthcare Investment Geography: Global (with a focus on the United States) Notable Investments: Editas Medicine, Bluebird Bio, InterMune, Amylin Pharmaceuticals, GRAIL

2

Biopharma Funding & Emerging Start-Up Update June 10-14th ‘24 Newly launched biotechnology startups w/ ADC pipelines and more funding events… Get this weekly • https://lnkd.in/gDGtEEyy – 𝐏𝐫𝐢𝐯𝐚𝐭𝐞 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – Santa Ana Bio, Inc. 💸  Launched with $168 million in funding from combined Series A and B rounds to advance its precision immunology pipeline. The lead asset is SAB03, targeting autoimmune and inflammatory diseases, clinical trials are planned for 2025. Amber Therapeutics 💸  Closed $100M Series A funding led by New Enterprise Associates (NEA) to advance Amber-UI for Mixed Urinary Incontinence (MUI) through pilot and pivotal studies toward regulatory approval in the US. Alzheon, Inc. | Preserving Future Memories 💸  Raised $100M in Series E round led by Alerce Medical Technology Partners to fund the completion of its Ph 3 study for lead candidate (ALZ-801) for Alzheimer's disease (AD) later this year. Adcytherix 💸  Launched with €30M in seed funding led by Pontifax to develop next-generation novel ADCs for the treatment of different diseases such as cancer. Moleculent 💸  Launched with $26M Series A financing led by ARCH Venture Partners to study cell-to-cell interaction.  – 𝐏𝐨𝐬𝐭-𝐈𝐏𝐎/𝐏𝐮𝐛𝐥𝐢𝐜 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – Avidity Biosciences, Inc. 🏦  Announced pricing of $400.9M public offering. Ultragenyx 🏦  Announced pricing of $350M public offering. Abeona Therapeutics 🏦  Filed for $300M securities offering to fund BLA resubmission and pz-cel commercialization Disc Medicine 🏦  Announced  $178M public offering. Replimune 🏦  Announced $100M private placement financing to support a potential launch of RP1. At BiopharmIQ by Amp we maintain biopharma data to help with your sales/BD activities. 📰 Each week we share clinical/regulatory/funding news in an easy-to-digest format. #biotech #biopharma

18

1 Comment

Biotech Restructuring: Leading Through Ambiguity - https://lnkd.in/eiE7mnrT - By Denise Mueller, Chief Business Officer, Affimed Focus on careful growth strategies so investments create valuable and reliable data, which will not only bring good returns but also attract future investments.

78

4 Comments

As the 2024 investment year rolls on, we would like to take the time to highlight a few of our awesome committee board members! Parisa Khosropour is a Senior Life Science Executive with over 25 years of progressive career distinguished by architecting and executing strategies within the HealthCare and Life Sciences industries. She has built a reputation as a senior executive who provides leadership and direction for medical diagnostics/healthcare organizations to drive improvements and overcome obstacles to meet long-term financial and operational goals. Sara Zolfaghari is an entrepreneur, investor and two-time founder of health and wellness companies. She studied and worked in the pharmaceutical industry for 8 years, before starting her first company, nature soothie®. After successfully exiting her first company, she joined Tech Coast Angels, Los Angeles, as a member to support start-ups growing their businesses. Katherine Przygode is an angel investor, board member and advisor to various startups. Katherine is a proven tech entrepreneur with over 25 years of experience running IT departments for a host of Silicon Valley startups including match.com, myplay.com, and wagerworks.com among others. As an early cloud computing adopter, Katherine was the CEO and founder of one of the first AWS Managed Services Providers and resellers which she exited to a leading Private Equity firm. Lauren Accordino formerly ran Corporate Development and Strategic Operations at Carvana. Prior to that she worked Jones Day in the Business Restructuring & Reorganization Group where she lead business development. Lauren worked in investment banking at Montgomery & Co., advising growth stage companies on M&A and Private Placements in the digital media and technology sectors. She started her career in the analyst program at Morgan Stanley in New York City on the trading floor of the Institutional Equity Division. Min-Yi Shih is a dynamic technologist, an accomplished business executive, an investor, and a business advisor. Dr. Shih has a background in Physics and earned his Ph.D. in Electrical Engineering from Pennsylvania State University, he also attained his EMBA from the University of California, Los Angeles, Anderson. Dr. Shih has a wealth of experience in executive roles such as CTO and COO across various industries including R&D, defense, medical, and communication equipment. Jorge Rodriguez is an accomplished medical doctor and dedicated clinician based in the Los Angeles area, with over a decade of experience in patient care. He has earned recognition as the first author of published research in basic science, with a focus on protein signaling and inflammation pathways. Throughout his medical training, Dr. Rodriguez concentrated on international medicine, providing compassionate care to patients across Latin America, Europe, and Africa. 

60

12 Comments

ChrysCapital Looks to Sell GeBBS Healthcare Solutions for $1B - HIT Consultant #ChrysCapitalSellGeBBSHealthcareSolutions ChrysCapital, a private equity firm, is considering selling GeBBS Healthcare Solutions for $1 billion. This potential deal is attracting attention in the healthcare IT industry as it could have significant implications for the future of GeBBS Healthcare Solutions. #GeBBSHealthcareSolutionsOverview GeBBS Healthcare Solutions is a leading provider of healthcare outsourcing solutions, specializing in revenue cycle management and healthcare IT services. The company has a strong track record of delivering high-quality services to healthcare organizations across the United States. #PotentialImpactofSale If ChrysCapital successfully sells GeBBS Healthcare Solutions for $1 billion, it could lead to changes in the company's leadership, strategic ai.mediformatica.com #healthcare #this #acquisition #busine #india #outsourcing #equity #privateequity #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/4aGZ4bZ)

1

Here is Matt's BioBusiness update for last week. It focuses on business deals, fund raises and more, across medical devices, biotech and drug discovery. #medicaldevices #biotech #drugdiscovery

2

𝗨𝗻𝘃𝗲𝗹𝗹𝗶𝗻𝗴 𝗥𝗲𝗰𝗲𝗻𝘁 𝗙𝘂𝗻𝗱𝗶𝗻𝗴,𝗠&𝗔 𝗮𝗻𝗱 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀-𝗝𝘂𝗻𝗲𝟮𝟬𝟮𝟰 Foresite Capital raises a $900 million fund focused on precision medicine and healthcare infrastructure. Vaxart, Inc. shares surged 128% after receiving up to $453 million from a BARDA-funded consortium to develop rapid response medical solutions. Telix Pharmaceuticals Limited withdraws its planned $200 million Nasdaq IPO deciding it was not beneficial under current market conditions. Roche partners with Ascidian Therapeutics on RNA exon editing drugs, investing $42 million upfront with up to $1.8 billion in milestone payments. Grifols sells a 20% stake in Shanghai RAAS Blood Products Co.,Ltd. to Haier Group for $1.72 billion, maintaining a 6.58% stake and a board seat. European Renal Association (ERA) secures 665,000 avian flu vaccines, with options for 40 million more. US,EU pledge $2B + to help boost vaccine manufacturing in Africa Life sciences investor Decheng Capital targets $700M for fifth fund. UK BiotechNet raises $80M to advance early-stage rare eye cancer treatment. Samsung Biologics and Baxter International Inc. dial uo manufacturing deal to $223M. Can mRNA be harnessed for gene insertion?Moderna’s former chief medical officer has $82M to find out. Exsilio Therapeutics Novo Nordisk budgets $4.1B for new Us manufacturing site as it abandons plans for Irish build. Alexis Borisy and Zach Weinberg Curie.Bio secures $380M to support portfolio's Series A rounds. Zealand Pharma rides obesity wave with $1B raise to advance amyling drug and look for a partner. Adam Steensberg, MD, MBA. With a $372M megaround ,Formation Bio looks to in-license 10+drugs. Benjamine Liu

13

Check it out: our co-founder and chief scientific officer Ethan Weiss joined Brad Loncar and BiotechTV to chat all things Marea, the risk of remnant cholesterol and how we are combining human genetics and adipose biology to develop novel therapies for patients at risk for heart attacks even after controlling classical risk factors such as #obesity and elevated LDL #cholesterol. Listen below. 

23

2 Comments

Recently, Dr. Alexandra MacLean, CEO of Avenue Therapeutics, hosted Dr. Christopher Grunseich (National Institute of Neurological Disorders and Stroke) and Dr. Tahseen Mozaffar (UC Irvine) in a virtual key opinion leader event to discuss #SpinalBulbarMuscularAtrophy (#SBMA), also known as #KennedysDisease. Currently, there are no FDA approved treatments for this rare neurodegenerative disease. The event focused on the current understanding of the condition including unmet needs, and an overview of Avenue’s Phase 1/2a trial of #AJ201 for the treatment of #KennedysDisease. Click here to view a replay of the event: https://lnkd.in/e5ZiDaiW

13